02:12 PM EDT, 04/04/2024 (MT Newswires) -- ADC Therapeutics ( ADCT ) rose past 10% in recent Thursday trading after the company said it completed dose escalation in its phase 1b trial of Zynlonta plus glofitamab or mosunetuzumab in patients with relapsed/refractory B-cell non-hodgkin lymphoma.

There were no dose-limiting toxicities, no or low-grade cytokine release syndrome, and no immune effector cell-associated neurotoxicity syndrome during this part of the trial, the company said.

Based on the data, all three dose levels have been cleared and enrollment in phase 2 dose expansion has been initiated, it said.

Price: 4.88, Change: +0.45, Percent Change: +10.19